Especially when it comes to news about COVID-19 and even more especially news about the vaccines against SARS-Co-V-2.
So, many of the headlines that followed a study published this week in the New England Journal of Medicine about the Pfizer vaccine’s effects on the viral stain from South Africa called (B.1.351) focused on the fact that the study (done in a lab on blood drawn from people who had antibodies against SARS-CoV-2) found that “the levels of neutralization against the South African variant fell up to 2/3” (compared to immunity against the previously-prevalent virus strain).
But here’s the thing: Given how much “spare” immunity seems to be generated by these vaccines, what the researchers concluded was that it’s still very likely Pfizer-BioNTech’s Covid-19 vaccine can protect people against these new variants, including the one from South Africa.
The game is still on.
Memo to Canada: immunize us.